European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?","authors":"Priscilla Guglielmo, Laura Evangelista","doi":"10.1007/s00259-025-07254-7","DOIUrl":"10.1007/s00259-025-07254-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3935-3937"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET imaging of TREM2 in amyloid-beta induced neuroinflammation.","authors":"Amelia D Dahlén, Sahar Roshanbin, Ximena Aguilar, Nadja M Bucher, Sara Lopes van den Broek, Dag Sehlin, Stina Syvänen","doi":"10.1007/s00259-025-07358-0","DOIUrl":"10.1007/s00259-025-07358-0","url":null,"abstract":"<p><strong>Purpose: </strong>The triggering receptor expressed on myeloid cells 2 (TREM2) has become a promising target for biologics in both monitoring and treating neuroinflammation in Alzheimer's disease (AD). This study aimed to develop and compare bispecific anti-TREM2 antibodies featuring different transferrin receptor (TfR) binders to enhance brain delivery, identifying the most suitable format for in vivo PET imaging of TREM2 in transgenic AD mice.</p><p><strong>Methods: </strong>Three bispecific TREM2-antibody formats were produced and evaluated for their ability to cross the blood-brain barrier (BBB) via TfR-mediated transcytosis and bind TREM2. Blood concentration profiles up to 72 h post-injection (p.i.), and ex vivo brain uptake of iodine-125-labeled antibody constructs were quantified in App^NL-G-F and age-matched wild type (WT) mice using a γ-counter. The best-performing bispecific TREM2-antibody was radiolabeled with iodine-124 and used for in vivo PET imaging of brain TREM2 levels in App^NL-G-F mice at 72 h p.i. Brain TREM2 concentrations were subsequently quantified using ELISA.</p><p><strong>Results: </strong>The antibody format carrying two scFv8D3 TfR-binders (IgG-scFv₂), demonstrated the highest brain concentrations of all tested bispecific constructs. This antibody also exhibited significantly higher brain concentrations in App^NL-G-F mice compared to WT mice at both 48 and 72 h p.i. This difference was further visualized and quantified through in vivo PET imaging. Moreover, brain concentrations of the antibody ligand correlated with elevated TREM2 levels in brain homogenates.</p><p><strong>Conclusion: </strong>These findings highlight IgG-scFv₂ as a promising radioligand for in vivo PET imaging of TREM2, advancing non-invasive neuroinflammation studies and supporting drug development for AD and other neurodegenerative diseases.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4320-4333"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia.","authors":"Silvia Carraro, Valentina A Ferraro, Pietro Zucchetta, Stefania Zanconato, Francesca Serani, Chiara Giraudo, Diego Cecchin","doi":"10.1007/s00259-025-07521-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07521-7","url":null,"abstract":"<p><strong>Background: </strong>Primary ciliary dyskinesia (PCD) is a rare condition characterized by ciliary dysfunction, impaired mucociliary clearance and mucus accumulation in the airways.</p><p><strong>Purpose: </strong>Our aim was to evaluate the performance of [18F]FDG PET/MR in assessing structural and inflammatory pulmonary features in patients with PCD, using high-resolution CT (HRCT) as the gold-standard reference.</p><p><strong>Materials and methods: </strong>We recruited patients with PCD (≥ 7 years) regularly followed at our Regional Center for PCD. They underwent chest HRCT and [18F]FDG PET/MR using sequences optimized for the morpho-functional study of the lung. Parametric PET images were obtained by dividing each voxel by the mean value in a reference area. The volume of interest (VOI in cm³), named Metabolic Inflammatory Volume (MIV), was calculated by thresholding the PET parametric image using a value twice the mean of the reference area. Standardized Uptake Value (SUV) Max, SUV mean, Total Lesion Glycolysis (TLG) and MIV were recorded. HRCT and MR were analyzed using the Eichinger score.</p><p><strong>Results: </strong>Sixteen patients were enrolled. The Bland-Altman plot showed good agreement between HRCT and MR scores. Cumulative HRCT and MR scores correlated significantly with SUV mean score (HRCT: p = 0.02, r_s=0.6; MR: p = 0.006, r_s=0.66) and MIV (HRCT: p = 0.003, r_s =0.7; MR: p = 0.004, r_s =0.69). Total HRCT and MR scores and MIV score inversely correlated with spirometric parameters.</p><p><strong>Conclusion: </strong>PET/MR proved to be accurate in evaluating disease extent in PCD. It enabled the simultaneous assessment of structural damage and lung inflammation, both of which resulted inversely related to lung function. PET/MR is a promising tool for PCD monitoring.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis, preclinical evaluation, and clinical translation of [⁶⁸Ga]Ga-Asp₂-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms.","authors":"Zihao Chen, Xingyu Mu, Lei Zhang, Zhisheng Jie, Kadeer Tudi, Haoran Liang, Qingxing Liu, Jingze Li, Weixia Chong, Yufeng Mo, Wei Fu, Ganghua Tang","doi":"10.1007/s00259-025-07474-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07474-x","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp&lt;sub&gt;2&lt;/sub&gt;-PEG&lt;sub&gt;2&lt;/sub&gt;- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 was synthesized by modifying the NOTA-JR11 backbone, and its binding properties were evaluated via molecular docking, in vitro assays, and in vivo imaging. Radiolabeling with &lt;sup&gt;68&lt;/sup&gt;Ga was performed for Asp&lt;sub&gt;2&lt;/sub&gt;-JR11, NOTA-JR11, and DOTA-TATE. We conducted cell uptake, internalization, PET/CT imaging, biodistribution, and blocking studies in AR42J (SSTR2-positive) and HCT116 (SSTR2-negative) tumor models. A first-in-human study included nine patients with NENs who underwent [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 PET/CT and [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT imaging, along with dosimetry assessment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Docking analysis showed that Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 maintained equivalent binding energy to NOTA-JR11 but formed more hydrogen bonds with SSTR2 (10 vs. 5), suggesting enhanced stability. [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 demonstrated high radiochemical purity (&gt; 95%), higher molar activity (12.9-14.8 GBq/µmol), and greater hydrophilicity (LogD = - 3.18 ± 0.01) than comparators. In AR42J cells, [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 exhibited rapid uptake (9.95 ± 0.10%AD/10⁶ cells at 30 min) and low internalization (17.63 ± 0.91% at 120 min), with significantly higher uptake than [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTA-TATE and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-NOTA-JR11 in both in vitro and micro PET/CT studies (e.g., 10.67 ± 0.16 vs. 7.79 ± 0.50%ID/g at 30 min, p &lt; 0.05). In vivo imaging and biodistribution confirmed higher tumor-to-background ratios and reduced off-target organ uptake, notably in the kidneys, pancreas, and spleen. Tumor uptake was significantly inhibited by co-injection of SSTR2 ligands, confirming specificity. In human subjects, [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Asp&lt;sub&gt;2&lt;/sub&gt;-JR11 showed favorable biodistribution and rapid clearance via renal excretion, with the spleen showing the highest transient uptake. Tumors were clearly visualized as early as 12 min post-injection and maintained strong contrast up to 120 min. Dosimetry revealed the highest absorbed dose in the urinary bladder wall (5.78 × 10⁻² mSv/MBq), with an effective whole-body dose of 9.94 × 10⁻³ mSv/MBq. Comparative PET/CT imaging in nine patients (33 ","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The importance of developing multiparametric prognostic scores to stratify coronary risk by means of artificial intelligence.","authors":"Guillermo Romero-Farina, Santiago Aguadé-Bruix, C David Cooke, Ernest V Garcia","doi":"10.1007/s00259-025-07510-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07510-w","url":null,"abstract":"<p><p>Cardiovascular risk stratification is crucial, as it is a key predictor of morbidity and mortality. The development of multiparametric scores for coronary risk stratification, integrated with artificial intelligence (AI), is important because it facilitates assessment in clinical practice. Therefore, prognostic coronary risk scores that incorporate multiple clinical variables and cardiac imaging data are necessary and deserve greater attention, as they provide a more comprehensive and accurate evaluation of individual patient risk across various clinical scenarios. Additionally, they support clinicians in making better-informed decisions based on a comprehensive assessment. Importantly, the widespread clinical use of multiparametric risk scores should be enabled by implementing standardized computer interfaces that can exchange the relevant imaging and clinical data needed to calculate these scores. The ongoing AI revolution, which increasingly relies on digital demographic, clinical, and imaging data, is rapidly making the availability of such data a reality.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.","authors":"Wendy Delbart, Ioannis Karfis, Marie Vercruyssen, Roland De Wind, Nathalie Meuleman, Zéna Wimana, Patrick Flamen, Erwin Woff","doi":"10.1007/s00259-025-07500-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07500-y","url":null,"abstract":"<p><strong>Purpose: </strong>This phase II study investigates the expression of somatostatin receptors (SSTR) in relapsing and refractory multiple myeloma (rrMM) patients for potential radiotheranostic application.</p><p><strong>Methods: </strong>Seventeen triple-class exposed rrMM patients who demonstrate [¹⁸F]F-FDG avidity were prospectively included. Patients underwent a [⁶⁸Ga]Ga-DOTATATE PET/CT within 4 weeks after [¹⁸F]F-FDG PET/CT, which was performed as part of the standard workup. Focal lesions (FLs) were identified on both scans and were defined as focal uptake higher than the femoral bone marrow background uptake. Peptide Receptor Radionuclide Therapy (PRRT) eligibility was determined based on the following criteria: absence of [¹⁸F]F-FDG-avid FLs without corresponding [⁶⁸Ga]Ga-DOTATATE uptake, identification of ≥ 3 [⁶⁸Ga]Ga-DOTATATE FLs, and no diffuse bone marrow uptake on [⁶⁸Ga]Ga-DOTATATE PET/CT.</p><p><strong>Results: </strong>All patients had measurable disease on [¹⁸F]F-FDG PET/CT. [⁶⁸Ga]Ga-DOTATATE uptake was observed in all patients, with FLs identified in 15 of the 17 patients. The combined [¹⁸F]F-FDG and [⁶⁸Ga]Ga-DOTATATE PET/CT analyses classified patients into 4 categories: (1) Identical FLs identified by both radiotracers; (2) All [¹⁸F]F-FDG FLs showed corresponding [⁶⁸Ga]Ga-DOTATATE uptake, with additional [⁶⁸Ga]Ga-DOTATATE FLs; (3) Only some of the [¹⁸F]F-FDG FLs showed [⁶⁸Ga]Ga-DOTATATE uptake; (4) Diffuse bone marrow uptake of [⁶⁸Ga]Ga-DOTATATE, preventing FLs identification. Patients in categories 1 and 2 were deemed PRRT-eligible if they had ≥ 3 FLs on [⁶⁸Ga]Ga-DOTATATE PET/CT. Consequently, 10 out of 17 patients (60%) met the PRRT eligibility criteria.</p><p><strong>Conclusion: </strong>In heavily pretreated rrMM patients showing avid disease on [¹⁸F]F-FDG PET/CT, [⁶⁸Ga]Ga-DOTATATE PET/CT identified 60% of patients as eligible candidates for PRRT, suggesting a potential new indication for PRRT in selected patients.</p><p><strong>Trial registration: </strong>NCT04379817, Registered on 4 May 2020, https://clinicaltrials.gov/study/NCT04379817?cond=multiple%20myeloma&term=scarlet&rank=1.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.","authors":"Johannes Lohmeier, Jenny Meinhardt, Helena Radbruch, Mauricio Reyes, Winfried Brenner, Anna Tietze, Marcus R Makowski","doi":"10.1007/s00259-025-07520-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07520-8","url":null,"abstract":"<p><strong>Purpose: </strong>The isocitrate dehydrogenase (IDH) genotype is crucial for diagnosing and managing adult-type diffuse glioma. We investigated spatial tumour characteristics in treatment-naïve glioma using an U-Net-based CNN and evaluated associations with metabolic dysfunction and IDH genotype.</p><p><strong>Methods: </strong>Between 2015 and 2024 patients with confirmed contrast-enhancing glioma were pre-operatively investigated using MRI or [18 F]FET PET/MRI. Automated morphometry using a U-Net-based CNN on standard MRI sequences (T1c, T1, T2, FLAIR) was performed. Contrast-enhancing tumour fraction (CTF), metabolic tumour volume (MTV), total tumour volume (TTV) were determined. Dice coefficient assessed volume intersections. Comparative and statistical analyses included non-parametric tests, ROC curves, regression, and correlation.</p><p><strong>Results: </strong>A total of 180 patients (male, 114; female, 66; age, M ± SD = 54 ± 15y; IDH-mutant, 63; IDH wild-type, 117) with treatment-naïve glioma were evaluated. [18 F]FET-PET metabolic activity correlated significantly with CTF (p < .05). IDH-mutant gliomas had lower CTF (p < .001) due to higher non-enhancing tumour mass (p < .001) relative to the enhancing mass, unlike IDH wild-type glioblastoma. The CTF predicted IDH genotype with high accuracy (AUC = 0.85, sensitivity 78%, specificity 90%) across datasets. Combining CTF with patient age or SUVmax further improved the classification (ΔAUC = 0.12, p = .02; ΔAUC = 0.09, p > .05). Subgroup analyses showed consistent performance across IDH-mutant subtypes. MTV from [18 F]FET-PET exceeded structurally apparent TTV (p = .033).</p><p><strong>Conclusion: </strong>Spatial mapping of treatment-naïve glioma identified a non-invasive biomarker, which is linked to metabolic dysfunction and enabled robust IDH-genotype classification from standard MRI, suggesting a central role for radiogenomic assessment in adult-type diffuse gliomas prior to surgery.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging based spatiotemporal dynamics progression of brain glucose metabolism in multiple system atrophy.","authors":"Xiaofeng Dou, Jing Wang, Daoyan Hu, Haotian Wang, Congcong Yu, Rui Zhou, Xiaohui Zhang, Qiong Yao, Mei Tian, Hong Zhang, Yan Zhong, Chentao Jin","doi":"10.1007/s00259-025-07509-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07509-3","url":null,"abstract":"<p><strong>Objective: </strong>Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with complex clinical manifestations, which is essential for patient management and mechanistic understanding of MSA. In this study, we aimed to use disease progression modeling (SuStaIn model) to elucidate the in vivo spatiotemporal progression patterns of brain glucose metabolism in MSA patients, and investigate the differential profiles of clinical characteristics and dopaminergic function among the identified progression-related subtypes.</p><p><strong>Methods: </strong>A total of 192 participants (117 MSA patients [70 MSA-P, 47 MSA-C] and 75 healthy controls) who underwent [¹⁸F]FDG PET scans, with 82 MSA patients additionally receiving [¹⁸F]FP-CIT PET imaging were retrospectively enrolled. [¹⁸F]FDG PET-based SuStaIn model was established to illustrate spatiotemporal evolutionary patterns of brain glucose metabolism using the cross-sectional data, and identified distinct metabolic subtypes. Metabolic subtypes and stages were correlated with motor function (UPDRS-III), cognitive function (MMSE, MoCA), autonomic symptoms, and dopamine transporter (DAT) activity.</p><p><strong>Results: </strong>The [¹⁸F]FDG PET-based SuStaIn model identified two robust spatiotemporal metabolic progression subtypes, with Subtype 1 enriched in MSA-C (52.0%, 39/75) and Subtype 2 in MSA-P (78.8%, 26/33). Subtype 1 was characterized by initial hypometabolism in the cerebellum, sequentially progressing to brainstem, striatum, and cortical regions. Subtype 2 demostrated a striatal-onset pattern, progressing sequentially to the brainstem, cerebellum, and frontal lobe. Despite comparable disease duration, subtype 1 patients exhibited significantly poorer cognitive performance (MMSE, FDR q = 0.013; MoCA, FDR q = 0.032) and reduced anterior-to-posterior putamen DAT ratios (FDR q < 0.001) compared to subtype 2. Conversely, subtype 2 patients showed more obvious motor deficits (UPDRS-III, FDR q = 0.042). Significant correlations were observed between SuStaIn progression stages and clinical features across all patients, including UPDRS-III (r = 0.322, p = 0.001), MMSE (r = -0.263, p = 0.009), and MoCA scores (r = -0.292, p = 0.004). These results were confirmed in an independent validation cohort.</p><p><strong>Conclusion: </strong>This study for the first time used [¹⁸F]FDG PET-based SuStaIn model to elucidate spatiotemporal dynamic progression of MSA, and identified novel metabolic subtypes. These findings provided metabolic evidence of the biological heterogeneity in MSA, which maybe helpful for patients managment and the understanding of mechanisms.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-MY6349 PET/CT-guided TROP2-targeted therapy in mCRPC.","authors":"Shanshan Wang, Wei Liu, Xudong Ni, Dingwei Ye, Shaoli Song, Yao Zhu","doi":"10.1007/s00259-025-07501-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07501-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined [¹⁸F]-FDG PET-MR imaging for monitoring small bowel crohn's disease.","authors":"Juho Mattila, Johanna Kallio, Eliisa Löyttyniemi, Pirjo Nuutila, Jukka Koffert","doi":"10.1007/s00259-025-07524-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07524-4","url":null,"abstract":"<p><p>Crohn's disease (CD) is a chronic and relapsing inflammatory disease of the gastrointestinal tract. Diagnostics and follow-up are difficult in small bowel, that can be only partially evaluated by conventional endoscopy. Combined positron emission tomography magnetic resonance enterography (PET-MRE) has shown potential in diagnosing small bowel CD, but its role in monitoring treatment response has not been previously established. This study aimed to evaluate whether PET-MRE can be used to assess the efficacy of medical therapy. We hypothesized that standardized uptake values (SUV) in inflamed small bowel segments would decrease following initiation of standard therapy. A total of 35 volunteer patients with clinically suspected small bowel CD were recruited. All patients underwent ileocolonoscopy and laboratory testing, followed by [¹⁸F]-FDG PET-MRE. CD diagnosis was confirmed by small bowel capsule endoscopy. Clinicians initiated treatment based on standard diagnostics, blinded to the PET results. Eighteen patients completed follow-up [¹⁸F]-FDG PET-MRE at three months. Maximum SUV (SUV_Max) was measured in the small intestine and compared with MRE findings. The median SUV_Max decreased significantly from baseline to follow-up (3.2 vs. 2.1, p = 0.0025). The Simplified Magnetic Resonance Index of Activity (sMARIA) was also significantly lower at follow-up (p = 0.001). Representatively, median fecal calprotectin declined (451 µg/g vs. 163 µg/g, p = 0.004). This preliminary prospective study suggests that [¹⁸F]-FDG PET-MRE may be a useful tool for assessing biochemical response to treatment in newly diagnosed small bowel CD.Trial registration number: NCT06796959 (ClinicalTrials.gov). Retrospectively registered on 21.1.2025. Enrollment of first participant on 1.8.2020.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}